Regenerative Medicine and Hormone Therapy: A Powerful Pairing

By Dr. Farhan Abdullah, DO | Medical Director, Magnolia Functional Wellness | Southlake, TX

Two patients, same shoulder, same procedure, same rehab protocol. One is back to overhead pressing by month four. The other is still guarding the joint at month eight, quietly wondering whether she wasted her money. I've watched that split happen enough times that I stopped blaming the technique. When healing stalls in someone who did everything right, the problem usually isn't what went into the joint. It's the body that received it.

That's the short version of why I no longer think about regenerative medicine and hormone therapy as separate services. At Magnolia Functional Wellness in Southlake, they've become one conversation. Not because pairing them is fashionable, and not because I'd rather sell two things than one, but because tissue repair is an endocrine event at least as much as it's a mechanical one. You can place excellent biologic material into a damaged joint. If the hormonal environment around that joint is hostile to building tissue, you've delivered a truckload of lumber to a construction site with no crew.

What follows is how I actually think about this pairing, including the parts of the evidence that don't flatter it. There are some. Any physician who tells you the data here is clean is selling you something.

Healing Is a Hormonal Process, Not Just a Structural One

Here's the piece patients rarely hear in an orthopedic office. Your tendons, cartilage, and bone are not inert scaffolding. They're metabolically active tissue, constantly being torn down and rebuilt, and the pace of that turnover is governed substantially by your sex hormones.

Estrogen influences collagen synthesis and the cross-linking that gives tendon its tensile strength. It affects how fibroblasts behave and how quickly the extracellular matrix remodels after injury. Testosterone drives protein synthesis and satellite cell activity in muscle, and androgen receptors show up in tendon and bone tissue too. Both hormones shape the inflammatory tone of the whole system, which matters enormously, because repair depends on inflammation resolving on schedule rather than smoldering for months.

Now consider who typically walks into a regenerative medicine consult. Somebody in their late forties, fifties, or sixties with a joint that has been complaining for a year. That's precisely the demographic in which sex hormone production has declined, often substantially, and often without anyone measuring it. A woman five years past her final period has lost most of her circulating estradiol. A man at sixty may be running half the testosterone he had at thirty.

So when I evaluate a patient for platelet-rich plasma or other orthobiologic options, one of my first questions isn't about the joint at all. It's about sleep, energy, libido, recovery from workouts, and whether anyone has ever run a full hormone panel. Those answers tell me something about the biological terrain I'm about to inject into.

There's a data point that made this concrete for me. In a 2025 prospective pilot study by Wilde and colleagues in JSES International, researchers ran hormone, vitamin, and metabolic panels on fifty patients before rotator cuff repair. Forty-three percent of them were hypogonadal (PMID 41049669). Not screened for it, not treated for it, just quietly walking around with low sex hormones on their way into a procedure that depends on tissue healing. Nearly half.

What the Evidence Actually Shows, Including the Parts I Don't Like

I want to walk through this carefully, because the honest picture is messier than the version you'll find on most clinic websites.

Start with the encouraging findings. In that same Wilde study, hypogonadal patients had significantly worse pain scores, worse Simple Shoulder Test scores, and worse American Shoulder and Elbow Surgeons scores six months after surgery than their eugonadal counterparts. Their structural healing rate was lower too (36 percent versus 63 percent), though that particular difference didn't reach statistical significance in a study this small. Interestingly, vitamin D deficiency and diabetes didn't track with outcomes the way hormone status did.

On the female side, a 2025 review by Percin et al. in JSES Reviews, Reports, and Techniques looked at 184 postmenopausal women followed for two years after rotator cuff repair. The 42 women taking estradiol at the time of surgery reported significantly better pain scores and Subjective Shoulder Values at two years than those who weren't, despite the two groups starting from statistically identical baselines (PMID 41647695). That's a retrospective single-surgeon series, so treat it as a signal rather than proof. But it's a signal pointing the same direction as the biology.

Now the uncomfortable part.

A 2026 propensity score-matched cohort study by Bcharah and colleagues in Orthopaedic Journal of Sports Medicine pulled national data on perimenopausal women and compared roughly 64,000 hormone therapy users against 64,000 matched controls. Hormone therapy users had higher rates of rotator cuff tears, bicipital tendinitis, and both lateral and medial epicondylitis, along with higher rates of surgical repair (PMID 42212202). That's the opposite of what the mechanism would predict.

What do I make of that? A few things. Database studies capture diagnoses, not disease, and women engaged enough with the medical system to be on hormone therapy are also women who get their shoulder pain worked up instead of ignoring it for three years. That's classic detection bias. Propensity matching narrows confounding, it doesn't eliminate it. Still, I'm not going to wave the finding away, and neither should you. It's a large, well-constructed study saying something inconvenient.

And on the men's side, a 2025 analysis by Johnson et al. in JSES International reviewed more than 33,000 male rotator cuff repair patients and found that men who'd filled testosterone prescriptions within a year of surgery had higher rates of 90-day readmission, revision surgery, prolonged opioid use, and frozen shoulder (PMID 41459022). The authors concluded that stopping testosterone before rotator cuff repair should be considered case by case.

Two studies suggesting hormone optimization helps healing. Two suggesting the picture is more complicated, at least around surgery. That's where the literature honestly sits in 2026. Anyone presenting this as settled is not reading the same papers I am.

How I Actually Sequence the Two

Given all that, here's what I do in practice, which is less dramatic than either the marketing or the skeptics would suggest.

I measure before I treat. Anyone considering an orthobiologic procedure at my clinic gets a hormone panel as part of the workup, alongside the usual metabolic markers. Total and free testosterone, estradiol, SHBG, thyroid with full panel, vitamin D, ferritin, fasting insulin, and hsCRP. Not because I'm going to prescribe hormones to everyone, but because I want to know what I'm working with. Roughly half the time, something is off that nobody has looked at.

I correct the obvious deficits first when time allows. If a patient has a genuinely low testosterone level with symptoms to match, or is a postmenopausal woman with no estradiol on board and no contraindication to therapy, I'd rather spend eight to twelve weeks establishing a stable hormonal baseline before we inject anything. Repair takes months. Starting that clock in a body that's actively catabolic doesn't make sense to me.

I treat inflammation and metabolic dysfunction as part of the same problem. Elevated hsCRP, poorly controlled blood sugar, and a body that never sleeps deeply will all blunt a regenerative procedure. Hormones are one lever. They're not the only one, and I've seen more procedures underperform because of insulin resistance than because of low testosterone.

I respect the surgical data. The pairing I'm describing applies to non-surgical, office-based regenerative care. If a patient is heading for an operating room, the Johnson findings above genuinely change the conversation, and that's a discussion to have with the operating surgeon, not with me alone.

I don't overstate what orthobiologics are. Platelet-rich plasma and related orthobiologic procedures are not FDA-approved treatments for arthritis or tendon disease. The evidence supporting them varies considerably by tissue, by preparation, and by how advanced the underlying degeneration is. I tell patients that plainly, before they pay for anything.

Who This Pairing Isn't For

Plenty of people. Let me be specific, because "we can optimize you" is exactly the kind of sentence that should make you suspicious.

If your hormone levels are genuinely normal for your age and clinical picture, adding hormone therapy to a regenerative protocol buys you nothing and adds risk. Normal is normal. I'm not chasing supraphysiologic numbers so a knee heals three weeks faster.

If you have a history of hormone-sensitive cancer, unexplained vaginal bleeding, active thromboembolic disease, or a handful of other exclusions, hormone therapy is off the table regardless of what your joint is doing. The joint is not the most important organ in the conversation.

If your imaging shows bone-on-bone, end-stage arthritis, no combination of hormones and biologics is going to regrow a joint surface. I'd rather tell you that in the consult than take your money and let you discover it at month six. Some patients need an orthopedic surgeon, and my job includes saying so.

And if you're a man planning rotator cuff surgery in the next several months, the timing of testosterone therapy is something to work out with your surgeon before we make any changes.

The Practical Takeaway

I've had this conversation dozens of times in the exam room, usually with someone in their fifties who's been to three providers and been handed a cortisone shot at each one. The framing that seems to land is this: your joint didn't fail in isolation. It failed inside a body that changed. Sometimes the joint needs direct help. Often the terrain needs attention too. Treating one and ignoring the other is how people end up disappointed by good procedures.

That doesn't mean everyone who wants a PRP injection needs testosterone replacement therapy, or that hormone therapy is a healing shortcut. The data, as I read it today, supports something more modest: hormone status is a meaningful variable in tissue repair, it goes unmeasured far too often, and measuring it costs a blood draw. That's a reasonable thing to know before you commit to a months-long recovery.

If you're weighing regenerative options for a joint that hasn't cooperated, or you've already tried something that underdelivered, it's worth asking whether anybody ever checked the underlying biology. Around Southlake I see a lot of active people in their fifties and sixties who are still playing tennis, still chasing grandkids around Bob Jones Park, still refusing to accept that this is just how it is now. I like treating those patients. They tend to do well, particularly when we look at the whole system instead of just the part that hurts.